News

Edwards Lifesciences has revealed that it will be developing a new manufacturing facility in Draper, Utah, which will enable it to expand its manufacturing and R&D capability. The

Sanofi Pasteur, the vaccines division of the sanofi-aventis group, has revealed that a single dose of influenza A (H1N1) 2009 monovalent vaccines, Panenza or Humenza, administered to children

Novartis has gained exclusive worldwide rights to market PTK 0796 as the potential first once-daily broad-spectrum antibiotic that can be given by intravenous (IV) infusion or oral tablet.

The FDA Antiviral Drugs Advisory Committee has recommended the approval of Pfizer’s Selzentry (maraviroc) tablets for use in treatment-naive adult patients with CCR5-tropic HIV-1 virus, as part of

NextPharma has expanded its core capabilities through the addition of clinical trial services at its San Diego, California facility. The company said that these new services mirror NextPharma’s

Bayer Schering Pharma has reported that it will provide its development candidate florbetaben, a PET (positron emission tomography) tracer, to AC Immune, to support a clinical trial in

Keryx Biopharmaceuticals (Keryx) has initiated phase 2 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Small

Plexxikon has initiated dosing of cancer patients with PLX3397 in its phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic

Ipsen and Spirogen have entered into a new agreement superseding their 2003 contractual relationship regarding the DNA minor groove binder, SJG-136 (now known as SG2000). The new agreement